Clinical Management of Argentine Hemorrhagic Fever using Ribavirin and Favipiravir, Belgium, 2020

Veliziotis, Ioannis; Roman, Alain; Martiny, Delphine; Schuldt, Gerlind; Claus, Marc; Dauby, Nicolás; Wijngaert, Sigi Van den; Martin, Charlotte; Nasreddine, Rakan; Perandones, Claudia; Mahieu, Romain; Swaan, Corien; Praet, Serge Van; Konopnicki, Déborah; Morales, María Alejandra; Malvy, Denis; Stevens, Etienne; Dechamps, Philippe; Vlieghe, Erika; Vandenberg, Olivier; Günther, Stephan; Gerard, Michèle

doi:10.3201/eid2607.200275

Cited by 22 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical practice, FPV has been reported for treatment of human infections with life-threatening hemorrhagic fever virus, such as Ebola virus [18] , Lassa virus [19] , Arenavirus [20] and SFTSV [15] , but only limited to case report or case series report with very small case number. Despite of FPV treatment benefit shown in the most recent RCT of SFTS [14] , the result was obtained under near-ideal test conditions in highly selected patient populations, for whom the behavior of patients and investigators are highly compliant and adherent, and non-representative of routine clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome

Yuan

Yao

et al. 2021

eBioMedicine

View full text Add to dashboard Cite

Background Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with high mortality, however with no effective therapy available. Methods The effect of favipiravir (FPV) in treating SFTS was evaluated by an integrated analysis on data collected from a single-arm study (n=428), a surveillance study (n=2350) and published data from a randomized controlled trial study (n=145). A 1:1 propensity score matching was performed to include 780 patients: 390 received FPV and 390 received supportive therapy only. Case fatality rates (CFRs), clinical progress, and adverse effects were compared. Findings FPV treatment had significantly reduced CFR from 20.0% to 9.0% (odds ratio 0.38, 95% confidence interval 0.23-0.65), however showing heterogeneity when patients were grouped by age, onset-to-admission interval, initial viral load and therapy duration. The effect of FPV was significant only among patients aged ≤70 years, with onset-to-admission interval ≤5 days, therapy duration ≥5 days or baseline viral load ≤1 × 10 6 copies/mL. Age-stratified analysis revealed no benefit in the aging group >70 years, regardless of their sex, onset-to-admission interval, therapy duration or baseline viral load. However, for both ≤60 and 60-70 years groups, therapy duration and baseline viral load differentially affected FPV therapy efficiency. Hyperuricemia and thrombocytopenia, as the major adverse response of FPV usage, were observed in >70 years patients. Interpretation FPV was safe in treating SFTS patients but showed no benefit for those aged >70 years. Instant FPV therapy could highly benefit SFTS patients aged 60-70 years. Funding China Natural Science Foundation (No. 81825019, 82073617 and 81722041) and China Mega-project for Infectious Diseases (2018ZX10713002 and 2015ZX09102022).

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome

Yuan

Yao

et al. 2021

eBioMedicine

View full text Add to dashboard Cite

show abstract

“…2 During the peak of the epidemic in Belgium, FVP was considered as an antiviral therapeutic option in our institution for the following reasons: (1) restricted access to remdesivir in Belgium; (2) low frequency of side-effects 4 ; (3) direct availability; and (4) our previous experience with FVP therapy in the management of Argentine Hemorrhagic Fever. 5 Here is reported the tolerability of FVP therapy in four critically ill patients.…”

Section: Tolerability Of Favipiravir Therapy In Critically Ill Patienmentioning

confidence: 94%

Tolerability of favipiravir therapy in critically ill patients with COVID‐19: A report of four cases

Dauby

Praet

Vanhomwegen

et al. 2020

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

“…It is a derivative of pyrazinecarboxamide as well as other antiviral drugs including T-1105 and T-1106 ( Zhu et al, 2018 ). Experimental studies had shown that favipiravir was effective against influenza viruses ( Pascua et al, 2019 ), yellow fever virus ( Furuta et al, 2013 ), foot and mouth disease virus ( Furuta et al, 2009b ), West Nile virus ( Escribano-Romero et al, 2017 ), arenaviruses ( Veliziotis et al, 2020 ), bunyaviruses ( Scharton et al, 2014 ) and alphaviruses ( Delang et al, 2014 ), enteroviruses ( Furuta et al, 2013 ), Rift Valley fever ( Borrego et al, 2019 ) and other flaviviruses ( Segura Guerrero et al, 2018 ).…”

Section: Rna Polymerase Inhibitorsmentioning

confidence: 99%

A review of medications used to control and improve the signs and symptoms of COVID-19 patients

Hushmandi

Bokaie

Hashemi

et al. 2020

European Journal of Pharmacology

View full text Add to dashboard Cite

In December 2019, an unprecedented outbreak of pneumonia associated with a novel coronavirus disease 2019 (COVID-19) emerged in Wuhan City, Hubei province, China. The virus that caused the disease was officially named by the World Health Organization (WHO) as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to the high transmission rate of SARS-CoV-2, it became a global pandemic and public health emergency within few months. Since SARS-CoV-2 is genetically 80% homologous with the SARS-CoVs family, it is hypothesized that medications developed for the treatment of SARS-CoVs may be useful in the control and management of SARS-CoV-2. In this regard, some medication being tested in clinical trials and in vitro studies include anti-viral RNA polymerase inhibitors, HIV-protease inhibitors, anti-inflammatory agents, angiotensin converting enzyme type 2 (ACE 2) blockers, and some other novel medications. In this communication, we reviewed the general characteristics of medications, medical usage, mechanism of action, as well as SARS-CoV-2 related trials.

show abstract

Clinical Management of Argentine Hemorrhagic Fever using Ribavirin and Favipiravir, Belgium, 2020

Cited by 22 publications

References 8 publications

Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome

Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome

Tolerability of favipiravir therapy in critically ill patients with COVID‐19: A report of four cases

A review of medications used to control and improve the signs and symptoms of COVID-19 patients

Contact Info

Product

Resources

About